Avosentan May Slow Progression of Diabetic Kidney Disease
American Society of Nephrology (ASN)A new drug called avosentan significantly lowers urinary protein excretion"”an important marker of kidney disease progression"”in patients with diabetic kidney disease, according to an international clinical trial appearing in the March 2009 issue of the Journal of the American Society Nephrology (JASN). The study's results suggest that avosentan may slow the progression of diabetic kidney disease and help prevent end stage disease.